The multi-agent clinical decision support system designed for metabolic, anabolic, and longevity medicine has onboarded 400 practitioners and 10 enterprise customers.
WASHINGTON–(BUSINESS WIRE)–Hormonaly.ai™, a clinical research intelligence platform purpose-built for metabolic, anabolic, and longevity medicine, today announced the opening of tiered enterprise API access to its clinical and research intelligence platform. Designed to meet the specialized needs of clinicians, researchers, and healthcare enterprises operating at the frontier of metabolic and longevity science, the platform launches with full English and Arabic language support and offers both U.S. and GCC data residency options.
The platform is already in production with more than 400 practitioners and 10 enterprise customers across clinic groups, telehealth networks, and compounding pharmacies. API access starts at $499 per seat per month, with volume-based enterprise tiers. Individual licensed practitioners receive free access to the platform’s core workspace.
“Saying ‘I don’t know’ with confidence’ is a feature, not a failure,” said Fady Hannah-Shmouni, MD FRCPC, Founder of Hormonaly.ai. “Our prescribers need to know when the literature is strong and when the model is just guessing. We separate those two scores on every answer.”
The launch arrives at an inflection point for the field. The FDA’s ongoing 503A Bulk Drug Substances Nominations review continues to reshape what compounding pharmacies can legally dispense, with BPC-157 and other widely prescribed peptides under active scrutiny – shifting compliance risk onto prescribers and pharmacies in real time. At the same time, surging GLP-1 demand has reset baseline patient volumes across primary care and metabolic clinics, exposing operational gaps that legacy systems were never designed to address.
The downstream consequences – protocol variability across providers, uneven adherence across sites, and rapidly expanding documentation obligations – have escalated from operational nuisances to board-level concerns. Hormonaly’s platform addresses these pressures directly, streamlining clinical workflows and grounding decision-making in evidence-based medicine to help providers maintain compliance, consistency, and quality of care at scale.
Evidence-Graded Output, Not Generative Guessing
The platform’s central technical output is one most clinical AI products avoid making: every response separates a GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) rating of the underlying literature from a model confidence score on the synthesis itself. The GRADE framework serves as a systematic, transparent methodology for rating the certainty of clinical evidence and the strength of recommendations.
Clinical and compliance teams can now distinguish “the literature is strong” from “the model is sure,” with the gap between them surfaced explicitly when the evidence is weak, as it often is in regenerative and emerging peptide categories.
Each query is decomposed into a structured PICO research question and executed against a curated evidence graph drawn from biomedical databases, indexed across 562,000 extracted evidence statements, roughly an order of magnitude larger than the typical hand-curated systematic-review corpus in this category. Every response returns with PMID-linked inline citations, GRADE ratings, and attribution to the specialized agents that produced it, including a dedicated peptide supply-chain integrity agent that cross-references compounded products against current 503A bulk substance status. The corpus is reviewed by a clinical advisory board led by Fady Hannah-Shmouni, MD FRCPC, a board-certified endocrinologist formerly a principal investigator at the National Institutes of Health.
Three Commercial Surfaces
Hormonaly is delivered through Helix (the clinical AI copilot), the Protocol Library (594 GRADE-rated intervention protocols spanning hormone optimization, peptide therapeutics, and regenerative medicine), and the Hormonaly API. The API is the primary commercial vehicle, with clinic groups, telehealth networks, and compounding pharmacies embedding it into EMRs, prescriber decision support, formulary review, patient counseling, and compliance workflows. Research organizations, CROs, and biotech teams use the same API for literature review, indication scouting, and regulatory submission support.
Enterprise deployments include admin controls, usage analytics, configurable evidence filters, and full audit logging of every query and citation returned.
“Cited, GRADE-rated answers, with audit trail, are the difference between hoping our prescribers are aligned and knowing they are. That’s the gap Hormonaly closed for us,” said John Forde, Clinic Owner, Apollo Clinic, Canada
Availability
Hormonaly.ai is available today at hormonaly.ai. Enterprise API access and technical documentation are available at hormonaly.ai/api-docs or by contacting [email protected].
About Hormonaly.ai™
Hormonaly.ai™ is the clinical and research intelligence platform built exclusively for metabolic, anabolic, and longevity medicine. The platform combines a multi-agent AI architecture, a curated evidence graph drawn from six biomedical databases, GRADE-rated synthesis, and real-time response latency to bring cited, governable clinical reasoning into enterprise healthcare workflows. Hormonaly is a member of the NVIDIA Inception Program and Google for Startups. Learn more at hormonaly.ai.
Hormonaly.ai is a clinical decision support platform intended for use by licensed healthcare professionals. It does not replace independent clinical judgment and is not a substitute for professional medical advice, diagnosis, or treatment.
Contacts
Media Contact
Fady Hannah-Shmouni, MD FRCPC
[email protected]
